The company
Compugen Ltd. -
CGEN · Nasdaq
CGEN stood above a rising 150-day average in 38 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 18.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $253K
- Officials’ trades on record
- 0
- Institutions holding
- 80 (+7)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 38 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Zurit LevineSVP, Business Development | sold | 1,875at $2.50 | 9 Jul 2026filed 13 Jul 2026 |
| Eran OphirPresident and CEO | sold | 5,000at $3.20 | 24 Apr 2026filed 27 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 2,000at $3.20 | 24 Apr 2026filed 27 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 2,000at $2.80 | 14 Apr 2026filed 15 Apr 2026 |
| Eran OphirPresident and CEO | sold | 5,000at $2.90 | 14 Apr 2026filed 15 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 3,125at $2.56 | 10 Apr 2026filed 13 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 3,125at $2.56 | 10 Apr 2026filed 15 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 5,375at $2.42 | 8 Apr 2026filed 9 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 2,500at $2.30 | 7 Apr 2026filed 9 Apr 2026 |
| Eran OphirPresident and CEO | sold | 5,625at $2.21 | 1 Apr 2026filed 3 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 3,500at $2.20 | 1 Apr 2026filed 3 Apr 2026 |
| Zurit LevineSVP, Business Development | sold | 11,875at $2.04 | 26 Mar 2026filed 30 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLCreduced · filed 13 Aug 2026 | 3,184,257$6.8M | -131,588−4.0% |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 1,877,500$4.0M | +244,512+15.0% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 1,051,986$2.3M | -1,243−0.1% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC.unchanged · filed 14 Aug 2026 | 1,020,000$2.2M | 00.0% |
| Taylor Frigon Capital Management LLCreduced · filed 23 Jul 2026 | 842,181$1.8M | -5,862−0.7% |
| ARK Investment Management LLCreduced · filed 14 Aug 2026 | 786,536$1.7M | -263,337−25.1% |
| Altshuler Shaham Ltdadded · filed 12 Aug 2026 | 521,625$1.1M | +517,625+12940.6% |
| TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026 | 512,419$1.1M | -9,168−1.8% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 415,668$890K | +302+0.1% |
| Atom Investors LPadded · filed 14 Aug 2026 | 303,526$650K | +258,155+569.0% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.